Marché mondial du traitement de la fièvre Q – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché du traitement de la fièvre Q

Selon un rapport publié par la Bibliothèque nationale de médecine (NLM) en 2020, environ 50 personnes sur 100 000 souffrent de fièvre Q aiguë chaque année, tandis qu'une personne sur 1 000 000 contracte la fièvre Q chronique en un an. On constate une augmentation du nombre de patients atteints de fièvre Q aiguë à l'échelle mondiale. Selon les statistiques de l'OMS, les dépenses mondiales de santé par habitant se sont élevées à 1 064 741 USD en 2017.

Français Data Bridge Market Research analyse que le marché du traitement de la fièvre Q, qui s'élève à 4 623,05 millions USD en 2022, devrait atteindre 6 778,4 millions USD d'ici 2030, à un TCAC de 4,90 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché du traitement de la fièvre Q  

Market Definition

Q fever is also known as the query fever. It is a type of bacterial infection which is caused by the Coxiella burnetiid bacteria. The bacteria which is causing this fever are found in animals such as cattle, sheep, and goats globally. Many of the patients witness no symptoms at all while in some cases; the infection can reoccur years later. The chronic Q fever is a more toxic form of Q fever that may damage heart, brain, lungs and can cause diabetes in some cases.  

Q-fever Treatment Market Dynamics

Drivers

• Increasing Cases of Q-fever

As per the data released by the Centers for Disease Control and Prevention (CDC), in 2019, 178 cases of acute Q fever, and 34 cases of chronic Q fever were stated in the U.S. According to the report published by the National Library of Medicine (NLM) in 2020, around 50 people out of 100,000 suffer from acute Q fever yearly while 1 person out of 1,000,000 suffers from chronic Q fever in one year. Additionally, people having farmworkers, low immunity, and old age people are more possibly to get Q fever.

• Growing Partnerships Between Organizations

The increasing partnerships or collaborations between several market players are boosting the growth of the market. For instance, Basilea Pharmaceutica Ltd. partnered with Shenzhen China Resources Gosun Pharmaceuticals Co. Ltd. and received a drug approval license in China from National Medical Products Administration for Basilea’s antibiotic Zevtera.

Opportunities

• Increasing Healthcare Expenditure

As per the statistics by the WHO, the global per capita healthcare expenditure resulted to USD 1,064.741 in the year 2017. The global healthcare expenditure per person increase from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country which amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. Furthermore, according to the projections by the Centres for Medicare & Medicaid Services (CMS), the projected average annual percent change associated with National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Moreover, the National Health Expenditures are expected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. This factor is helping in increasing the market growth.

Restraints/Challenges

• Lack of Awareness About Q-fever

Not much awareness about the disease can lead to the restriction of the market growth. Q-fever is not commercially popular; thus, people are not much aware of that. Thus, it hampers the market growth.

This Q-fever treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Q-fever treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, Pfizer Inc. and Myovant Science released an update regarding MYFEMBREE, a 1 mg drug for the treatment of severe pain, where they have stated that U.S. FDA has extended the period to review this drug.
• In 2022, Sanofi announced the launch of its Foundation S with the aim to develop a healthy and useful future for the current and upcoming generations.
• In 2022, Basilea Pharmaceutical launched its first-in-class antifungal program for providing necessary help to patients who are suffering from fungal and bacterial infection and cancer

Global Q-fever Treatment Market Scope

The Q-fever treatment market is segmented on the basis of type, treatment type, drugs, vaccines, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute Q-Fever
• Chronic Q-Fever

Treatment Type

• Medication
• Vaccinations
• Surgery

Drugs

• Doxycycline
• Ciprofloxacin
• Pefloxacin
• Others

Vaccines

• Live Attenuated Vaccine
• Purified Corpuscular Formalin-Inactivated Vaccine
• Soluble Vaccine
• Others

End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Q-fever Treatment Market Regional Analysis/Insights

The Q-fever treatment market is analyzed and market size insights and trends are provided by type, treatment type, drugs, vaccines, end user and distribution channel as referenced above.

The countries covered in the Q-fever treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific dominates the Q-fever treatment market because of the rise in the occurrence of chronic diseases such as cancer, diabetes, and bacterial infection in developing countries. 

North America is expected to witness significant amount of growth in the Q-fever treatment market because of the rise in the acceptance of pets. Additionally, the upsurge in the preventive treatments and care facilities for companion animals is further predicted to boost the growth of the Q-fever treatment market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Q-fever Treatment Market Share Analysis

The Q-fever treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Q-fever treatment market.

Some of the major players operating in the Q-fever treatment market are:

• EpiVax, Inc.(U.S.)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Sanofi (France)
• Bayer AG (Germany)
• Amway Corp. (U.S.)
• Zydus Group (India)
• Lilly (U.S.)
• Pfizer Inc. (U.S.)
• Abbvie Inc. (États-Unis)
• Société Bristol Myers Squibb (États-Unis)
• Abbott (États-Unis)
• Merck & Co., Inc. (États-Unis)
• Mylan NV (États-Unis)
•  Lupin (Inde)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Amneal Pharmaceuticals LLC. (États-Unis)
• Aurobindo Pharma (Inde)
• Teva Pharmaceutical Industries Ltd (Israël)
• Mayne Pharma Group Limited (Australie)
• Alembic Pharmaceuticals Limited (Inde)
• Novartis SA (Suisse)
• Yashica Pharmaceuticals Private Limited (Inde)
• Basilea Pharmaceutica SA (Suisse)

SKU-46698